Pasithea therapeutics announces the first cohort has completed the initial dosing in its phase 1 trial evaluating pas-004 in ras, nf1 and raf mutated cancers

Pasithea tx (nasdaq: ktta) phase 1 trial on pas-004 for ras, nf1, and raf mutated cancers completes initial dosing, with safety data expected in 2h 2024.

KTTA Ratings Summary

KTTA Quant Ranking